Rainbow Genomics has launched a polygenic and trait analysis for obesity management using whole genome sequencing

Genetic analysis of metabolic disorder, combined with assessment of nutritional traits and exercise adaptation, enables lifestyle changes to reduce obesity.

San Francisco, California, United States, September 19, 2022 /EINPresswire.com/ – US and Hong Kong-based Rainbow Genomics has launched a comprehensive genetic analysis program for obesity, including Whole genome sequencing To identify genetic differences associated with metabolic disorders, responses to food and nutrition, eating behavior and exercise adaptation.

Obesity is considered by many physicians to be a chronic disorder, with body mass index (BMI) considered one of the factors indicating high body fat and overweight. BMI is considered highly heritable, and more than 40-70% of the variance in BMI can be explained by genetic factors. Individuals who are overweight are at increased risk of developing diabetes, heart disease, stroke, and other metabolic diseases.

Part of the obesity risk is conferred by genetic variants including mutations in a single gene, and polygenic changes associated with multiple genes. Additional obesity risks are associated with genetic traits with strong behavioral characteristics, including appetite, eating behavior, and exercise adaptation.

The Rainbow Comprehensive Genetic Analysis of Obesity Program is part of the many reports that Rainbow has to offer adult 8000™ Whole Genome Sequencing Test. The test examines single-gene mutations and polygenic risks associated with metabolic disorders. In addition, multiple Asian-specific genetic traits are also identified, including genetic alterations associated with BMI, appetite, eating behavior, diet preferences, nutritional absorption abnormalities, and adaptation to different forms of exercise.

A comprehensive analysis of these findings supports patients at risk of obesity to adopt a modified diet and lifestyle that can reduce their risk. The multifaceted results are explained to patients in both English and simple Chinese by a genetic counselor. Patients with disease-causing mutations associated with obesity, metabolic disorders or cardiovascular disease will also be referred to specialist physicians for follow-up.

For more information about the Rainbow Comprehensive Obesity Genetic Analysis Program and the Rainbow Adult 8000™ Whole Genome Sequencing Test, please visit our website or email us at info@rainbowgenomics.com

About the rainbow test for whole genome sequencing

The test provides five clinical reports:

1. Personal health assessment

• crabs
• Cardiovascular disorders
• Endocrine system dysfunction, including diabetes and fatty liver
• Sleep disorders
• Hearing and eye disorders
• Skeletal and orthopedic disorders
• Immune system disorders
Abnormalities of the skin
Autoinflammatory disorders
• behavioral anomalies
• Neurological disorders including dementia and Alzheimer’s disease

2. Reproductive health assessment

• Male sterility
• Infertility in women

3. Complete genome carrier status

• Carrier screening analysis for disorders recommended by the American College of Obstetricians and Gynecologists and the American College of Medical Genetics

• Whole-genome vector analysis – mutations in 2,500 genes associated with recessive disorders that can be passed on to the patient’s children

4. Common disease risk assessment

Common complex diseases such as diabetes, heart attack and stroke are mainly caused by changes in multiple genetic variants (polygenic risk). However, these variants are highly ethnically specific. Polygenic risk assessment for specific ethnic groups such as Asians is challenging because there are very few publications using Asian patients and statistically significant healthy controls available.

• Rainbow Genomics’ expert sponsored polygenic variants are highly race-specific and supported by large-scale genomic association studies and replication studies using tens of thousands of patients and controls en masse from Asia, the United States, and European countries.

5. Pharmacogenomic evaluation of 185 drugs to improve clinical outcomes

• For chronic disorders, achieving risk reduction goals through improved medication adherence is critical. Pharmacogenetic evaluation enables high therapeutic efficacy by reducing side effects of drugs, which leads to better treatment outcomes.

6. Rainbow Comprehensive Obesity Genetic Analysis Program and Report

About Rainbow Genomics

rainbow genomics (www.rainbowgenomics.com) to provide clinically proven genomic and proteomic assays for Asian, Caucasian, mixed, and indigenous minorities. The company offers clinicians high diagnostic success, enabling timely treatment of patients who can benefit from immediate medical interventions.

Using a multi-platform approach, including proteomics, whole genomes, whole exomes, RNA, long reads, methylation, single-cell sequencing, Sanger sequencing, high-resolution microarray testing, high-density DNA array genotyping, and through several International in collaboration, Rainbow Genomics delivers diagnostic productivity that meets or exceeds the highest standards reported by leading US and European medical institutions.

All Rainbow Genomics testing is performed in highly complex clinical laboratories that are CLIA-certified and CAP-accredited. Patient privacy is protected through Rainbow’s HIPAA compliant clinical testing process.

Daniel Siew
rainbow genome
+852 3481 0977